Surface Oncology rises as U.S. FDA allows antibody clinical trial

Surface Oncology

01/12/2021 14:26

** Drug developer's shares  SURF.O  rise 1.7% to $5.87
premarket
    ** Surface Oncology says the U.S. FDA has cleared its
application for its antibody candidate, GSK4381562, to proceed
into a first-in-human clinical trial  urn:newsml:reuters.com:*:nGNX7QPLJW
    ** GlaxoSmithKline  GSK.L  had licensed exclusive rights to
develop and sell the antibody last year
    ** The antibody is designed to promote the activation of
certain immune cells, which can elicit a strong anti-tumor
response
    ** Stock down 37.6% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))